UC Merced Undergraduate Research Journal

Due to their frequent misidentification for other ailments, a lay audience is likely to be unfamiliar with Early-Onset Sarcoidosis (EOS) and Blau Syndrome (BS), their presentation, their nuances, or developments in their treatments. EOS and BS are two genetic disorders that have often gone misdiagnosed for other conditions such as Juvenile Arthritis or Sarcoidosis due to their similar presentations of granulomas and inflammation. While these two particular disorders confer the same symptoms as their counterparts, the causes for their mutations are subtly defined. It's only been in recent years that the true culprit causing these disorders has been found and addressed. Recent strides in medicine have been taken to properly identify these disorders from their imposters and treat their underlying causes.  An antibody known as Infliximab has shown untapped potential in the treatment for EOS and BS. It was only until recently that doctors and researchers questioned Infliximab's ability to treat EOS and BS, as this antibody is well known for treating other inflammatory conditions such as Crohn’s Disease. Multiple case studies have shown promising efficacy when treating EOS and BS with Infliximab, often resulting in total reduction of symptoms when using Infliximab alone. Other case studies involving Sarcoidosis and Infliximab have produced little to no progress, further establishing the distinct differences between EOS and BS from their doppelgangers.